NASDAQ · Shell Companies · USD

Drugs Made In America Acquisition II Corp. (DMII) Stock Analysis

Drugs Made In America Acquisition II Corp. (DMII) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DMII

$10.19

+$0.00 (+0.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DMII with… →

DMII Key Statistics

As of Oct 21, 2026

Trading

Open: $10.19
Previous Close: $10.19
Day's Range: 10.19–10.20
52-Week Range: 9.86–10.33
Volume: 411.46K

Valuation

Market Cap: $649.10M
P/E Ratio: 33.97
EPS (ttm): 0.30

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $4.19M
Shares Outstanding: 63.70M

Dividend and dates

Avg Volume: 99.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Drugs Made In America Acquisition II Corp. (DMII) has a market capitalization of $649.10M.

DMII Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+2.93%
2025 (partial year)	+0.20%

As of October 21, 2026.

DMII Valuation vs Shell Companies Median

Median of 309 stocks

Metric	DMII	Shell Companies median	vs median
P/E	33.97	49.16	31% below

Medians across 309 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Drugs Made In America Acquisition II Corp. (DMII) carries a market capitalisation of $649.10M. The company sits in the Financial Services sector, in the Shell Companies industry.

The 52-week range on file runs from $9.86 to $10.33. DMII last closed at $10.19 on October 21, 2026. That is $0.00 (+0.05%) against the previous close. The latest close sits 3.35% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Net income for the same year was $4.19M. Earnings per share on a trailing basis come to 0.3.

Valuation Assessment

The trailing P/E ratio stands at 33.97. That is 30.89% below the Shell Companies median of 49.16. The medians here are taken across 309 Shell Companies companies that report the metric.

The stored price history starts on December 3, 2025, and the total return since then is +3.14%.

Growth & Income

No dividend is on file for DMII.

So far in 2026 the total return is +2.93%.

Peer Comparison

Drugs Made In America Acquisition II Corp. (DMII) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Drugs Made In America Acquisition II Corp.	DMII	$649.10M	34.0
Vylor Inc.	VYLR	$49.89B	106.8
Churchill Capital Corp XI	CCXI	$621.61M	—
EQV Ventures Acquisition Corp. II	EVAC	$603.77M	34.4

The Shell Companies industry average P/E ratio is 49.2x. Drugs Made In America Acquisition II Corp. trades at a P/E of 34.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Shell Companies Stocks

VYLR

Vylor Inc.

$49.89B

CCXI

Churchill Capital Corp XI

$621.61M

EVAC

EQV Ventures Acquisition Corp. II

$603.77M

BCSS

Bain Capital GSS Investment Corp.

$596.26M

CEPF

Cantor Equity Partners IV, Inc.

$587.79M

CXII

Churchill Capital Corp XII

$577.16M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.11T

JPM

JPMorgan Chase & Co.

$890.13B

Visa Inc.

$765.68B

Mastercard Incorporated

$545.42B

BAC

Bank of America Corporation

$358.24B

View all Financial Services stocks →

About Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.